Literature DB >> 9579543

Overexpression of p53 protein in cutaneous T cell lymphoma: relationship to large cell transformation and disease progression.

G Li1, L Chooback, J T Wolfe, A H Rook, C A Felix, S R Lessin, K E Salhany.   

Abstract

The molecular mechanisms by which advanced cases of cutaneous T cell lymphoma (CTCL) (mycosis fungoides/Sezary syndrome) undergo large cell transformation (LCT) and develop the morphologic appearance of a large cell lymphoma, are undefined. We used immunohistochemical analysis and polymerase chain reaction/single strand conformational polymorphism to examine whether p53 mutations are associated with disease progression and LCT in CTCL. p53 protein immunohistochemistry was performed on 37 paraffin embedded biopsies from 27 patients with CTCL; LCT was present in 15 biopsies. Overexpression of p53 protein was found in 11 of 37 CTCL biopsies including 10 of 15 biopsies (67%) with LCT in which p53 staining was predominantly seen in large transformed cells. In contrast, p53 immunostaining was found in only one of 22 CTCL biopsies without LCT (p < 0.0004). Serial biopsies revealed acquisition of p53 expression following LCT in two patients in whom initial diagnostic biopsies without LCT were p53 negative by immunostaining. All p53 protein positive biopsies were from advanced lesions (cutaneous tumors or extracutaneous sites); none of 12 patch/plaque stage CTCL biopsies demonstrated p53 staining. Polymerase chain reaction/single strand conformational polymorphism and sequencing analysis of p53 exons 4-8 was performed in 11 cases where frozen tissue was available. No mutations were detected in six cases positive for p53 protein expression. These results suggest overexpression of p53 protein in LCT and disease progression of CTCL by a mechanism other than p53 gene mutation, in most cases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9579543     DOI: 10.1046/j.1523-1747.1998.00167.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  7 in total

1.  Comparative genome-scale analysis of gene expression profiles in T cell lymphoma cells during malignant progression using a complementary DNA microarray.

Authors:  S Li; D T Ross; M E Kadin; P O Brown; M A Wasik
Journal:  Am J Pathol       Date:  2001-04       Impact factor: 4.307

2.  Interleukin-16 as a marker of Sézary syndrome onset and stage.

Authors:  Jillian Richmond; Marina Tuzova; Ashley Parks; Natalie Adams; Elizabeth Martin; Marianne Tawa; Lynne Morrison; Keri Chaney; Thomas S Kupper; Clara Curiel-Lewandrowski; William Cruikshank
Journal:  J Clin Immunol       Date:  2010-09-28       Impact factor: 8.317

3.  p16(INK4a) gene alterations are frequent in lesions of mycosis fungoides.

Authors:  I C Navas; P L Ortiz-Romero; R Villuendas; P Martínez; C García; E Gómez; J L Rodriguez; D García; F Vanaclocha; L Iglesias; M A Piris; P Algara
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

4.  Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.

Authors:  Meghali Goswami; Madeleine Duvic; Alexis Dougherty; Xiao Ni
Journal:  J Cutan Pathol       Date:  2012-05       Impact factor: 1.587

5.  Implications of bax, fas, and p53 in the pathogenesis of early-stage mycosis fungoides and alterations in expression following photochemotherapy.

Authors:  Fatma Aydin; Yildiz Levent; Senturk Nilgun; Yuksel Esra Pancar; Turanli Ahmet Yasar
Journal:  Indian J Dermatol       Date:  2011 Sep-Oct       Impact factor: 1.494

6.  miR-122 regulates p53/Akt signalling and the chemotherapy-induced apoptosis in cutaneous T-cell lymphoma.

Authors:  Valentina Manfè; Edyta Biskup; Anne Rosbjerg; Maria Kamstrup; Anne Guldhammer Skov; Catharina Margrethe Lerche; Britt Thyssing Lauenborg; Niels Odum; Robert Gniadecki
Journal:  PLoS One       Date:  2012-01-03       Impact factor: 3.240

7.  TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides.

Authors:  Gitte Wooler; Linea Melchior; Elisabeth Ralfkiaer; Lise Mette Rahbek Gjerdrum; Robert Gniadecki
Journal:  Front Med (Lausanne)       Date:  2016-11-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.